JAK2V617F和CALR双突变在JAK2V617F等位基因负担较低的患者中更常见。 - Suppr

Suppr

超能文献

JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens.

作者信息

Mansier Olivier, Migeon Marina, Etienne Gabriel, Bidet Audrey, Lippert Eric

机构信息

a Laboratoire d'Hématologie , CHU de Bordeaux ;

b Hématopoïèse leucémique et cibles thérapeutiques, INSERM U1035, Université de Bordeaux ;

出版信息

Leuk Lymphoma. 2016 Aug;57(8):1949-51. doi: 10.3109/10428194.2015.1116122. Epub 2016 Jan 4.

DOI:10.3109/10428194.2015.1116122

PMID:26727159

Abstract

摘要

相似文献

JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens.JAK2V617F和CALR双突变在JAK2V617F等位基因负担较低的患者中更常见。

Leuk Lymphoma. 2016 Aug;57(8):1949-51. doi: 10.3109/10428194.2015.1116122. Epub 2016 Jan 4.

Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.携带CALR、JAK2V617F、JAK2Ex12del和MPLW515L/K突变的日本真性红细胞增多症和原发性血小板增多症患者的临床特征。

Leuk Res. 2016 Jan;40:68-76. doi: 10.1016/j.leukres.2015.11.002. Epub 2015 Nov 10.

Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.中国CALR突变型骨髓增殖性肿瘤患者的频率、实验室特征及粒细胞活化

PLoS One. 2015 Sep 16;10(9):e0138250. doi: 10.1371/journal.pone.0138250. eCollection 2015.

A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.一项比较CALR突变型和JAK2V617F突变型原发性血小板增多症临床特征及预后的荟萃分析。

Int J Hematol. 2015 Feb;101(2):165-72. doi: 10.1007/s12185-014-1724-6. Epub 2014 Dec 25.

JAK2V617F mutation is associated with special alleles in essential thrombocythemia.JAK2V617F 突变与特发性血小板增多症中的特殊等位基因有关。

Leuk Lymphoma. 2011 Mar;52(3):478-82. doi: 10.3109/10428194.2010.542260. Epub 2011 Feb 1.

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.原发性血小板增多症和真性红细胞增多症中的驱动突变（JAK2V617F、MPLW515L/K或CALR）、五聚体蛋白3和C反应蛋白。

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.

Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia.既往三阴性原发性血小板增多症中JAK2V617F突变的发生情况

Leuk Lymphoma. 2017 Feb;58(2):503-504. doi: 10.1080/10428194.2016.1196816. Epub 2016 Jun 27.

The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.JAK2V617F突变对原发性血小板增多症患者不同类型血栓形成风险的影响：一项荟萃分析。

Int J Hematol. 2015 Aug;102(2):170-80. doi: 10.1007/s12185-015-1808-y. Epub 2015 May 22.

[Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):416-20.

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).JAK2V617F突变负荷对中国JAK2V617F阳性真性红细胞增多症（PV）和原发性血小板增多症（ET）患者疾病表型的影响

Int J Med Sci. 2016 Jan 25;13(1):85-91. doi: 10.7150/ijms.10539. eCollection 2016.

引用本文的文献

Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2 variant allelic fraction in a real-world cohort.分子特征在真实世界队列中对JAK2变异等位基因分数低的骨髓增殖性肿瘤患者诊断中的贡献

Ann Hematol. 2025 Mar;104(3):1587-1596. doi: 10.1007/s00277-025-06326-w. Epub 2025 Apr 1.

Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia.伊马替尼治疗慢性髓性白血病揭示了一种先前存在的CALR突变型原发性血小板增多症。

Hemasphere. 2018 Feb 5;2(1):e29. doi: 10.1097/HS9.0000000000000029. eCollection 2018 Jan-Feb.

The Role of New Technologies in Myeloproliferative Neoplasms.新技术在骨髓增殖性肿瘤中的作用

Front Oncol. 2019 Apr 26;9:321. doi: 10.3389/fonc.2019.00321. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验